Connected Health and Wearables Catalyse Adoption of Sensors in Healthcare Applications

The growing demand for quality healthcare has revolutionised the health monitoring space through use of wearable and ingestible sensors. Emphasis on preventive health has lead to the development of prognostic sensors for applications in medical space. This has lead to the shift of healthcare business model from a diagnostic one to more prognostic and preventive health and wellness. Sensor adoption is crucial to this evolution, facilitating advanced diagnostics, treatment, and patient monitoring. Wearable and implantable biosensors will emerge as the key enablers for device innovation, as well as will be commercialised as prognostic tools.

"The Internet of Medical Things will lead to sensors playing a greater role in offering connected healthcare infrastructure," said Measurement and Instrumentation Industry Principal Dr. Rajender Thusu. "However, there are no clear policies or standardisations yet that companies can adhere to while implementing the connected health platform. The greatest challenge, therefore, lies in bringing together different applications under the same working platform, when individual solutions lack interoperability."

 

Global Sensors Market in Healthcare and Medical Applications, Forecast to 2022, recent research from Frost & Sullivan's Sensors & Instrumentation Growth Partnership Service programme, examines different sensors in use and under development for healthcare and medical applications. Along with market, technology and economic trends, the study looks at the competitive landscape for existing participants and scope for entrants. The study covers wired and wireless sensor types, such as pressure, temperature, flow, accelerometer, image, squid, encoder, biosensor, humidity, force, magnetic, infrared, gas, inertial, optical, motion and alcohol, and others, which are used in clinical and health applications. Biosensors applications covered include point-of-care diagnostics, therapeutics, drug discovery, human genomes, protein detection, and genetic analysis.

Click here for complimentary access to more information on this analysis and to register for a Growth Strategy Dialogue, a free interactive briefing with Frost & Sullivan's thought leaders.

The sensors market for healthcare is expected to grow at a compound annual growth rate (CAGR) of 13.1 percent from 2016 to 2022. Market majors such as GE HealthcareHoneywellPhilips, and STMicroelectronics are investing heavily in internal research and development initiatives to comply with quality specifications and develop a connected health platform that can tackle interoperability issues. Collaborating with universities and independent research organisations offers a way to create standards for seamless connectivity.

"The other challenge that sensor manufacturers must tackle is the breakneck speed of medical research; billions of dollars are ploughed into developing invasive and non-invasive techniques to detect and treat patients suffering from new diseases caused by evolving pathogens," noted Measurement and Instrumentation Industry Analyst Nandini Bhattacharya. "Sensors must keep pace with these requirements."

Overall, the growth opportunities for sensors in healthcare and medical applications are expanding:

  • The transition of patient care from hospital to home offers strong opportunities in the home diagnostic and consumer healthcare segments.
  • Explosive growth in wearables will be mirrored in the demand for sensors.
  • Biosensors will be in demand for test applications for glucose, A1C, cholesterol, drugs of abuse, infectious disease, and pregnancy. The segment already accounts for more than 50 percent of the total global market share and will continue its robust growth.
  • The market provides strong opportunities for low-cost sensor manufacturers and startups offering innovative products for emerging applications.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. 

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.